Topline results show MyopiaX light stimulation safe, tolerable in children
Click Here to Manage Email Alerts
Key takeaways:
- Over 6 months, MyopiaX was safe and tolerable in a proof-of-concept trial of 124 children with myopia.
- The digital intervention uses targeted photobiomodulation to stimulate specific cells in the eye.
Dopavision has announced positive topline results from a proof-of-concept trial of MyopiaX, a noninvasive photobiomodulation intervention designed to slow myopia progression in children.
“The 6-month outcomes represent a significant step in the clinical development of MyopiaX,” Ian Flitcroft, PhD, FRCOphth, coordinating investigator of the MyopiaX-1 trial, said in a company press release. “The results are an important addition to the existing evidence supporting the mechanism of action of MyopiaX light stimulation.”
According to the release, the trial enrolled 124 children with myopia from six European countries, who were randomly assigned 2:1 to MyopiaX or control. Over 6 months, MyopiaX showed signs of clinical effect on the rate of myopia progression and was safe and tolerable, with no ocular safety events reported.
MyopiaX is designed to stimulate specific cells in the eye to regulate innate signaling pathways and slow myopia progression, the company stated, integrating myopia treatment into daily routines with a child-friendly digital platform.
“The 6-month findings of the MyopiaX-1 trial mark a monumental achievement for Dopavision,” CEO Mark Wuttke, PhD, said in the release. “With MyopiaX, our goal is to enrich myopia management for millions of children worldwide, providing a safe, noninvasive and engaging alternative that empowers young people to build a healthier, brighter future.”
The MyopiaX-1 trial is ongoing and expected to be complete in September, the company stated.
Read more about
Click Here to Manage Email Alerts